Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Thailand
UK
Ukraine
Orion Corporation (business code 1999212-6) has received a disclosure under Chapter 2, Section 9 of the Securities Markets Act, according to which the total number of the voting rights of the Orion shares owned by Erkki Etola and a company controlled by him, has in consequence of the share conversion under the Articles of Association of Orion Corporation executed on 7 November 2011 exceeded the one twentieth (1/20) threshold of the total number of Orion Corporation voting rights.
The total holding of Erkki Etola and the company controlled by him according to the disclosure (percentages rounded):
| Share type | Number of shares | Percent (%) of total shares | Percent (%) voting rights | |||
| A share | 2,500,000 | 1.77 | 5.00 | |||
| ISIN:FI0009014369 | ||||||
| Etola Oy | 2,300,000 | 1.63 | 4.60 | |||
| Erkki Etola | 200,000 | 0.14 | 0.40 | |||
| B share | 0 | 0 | 0 | |||
| ISIN:FI0009014377 | ||||||
| Total | 2,500,000 | 1.77 | 5.00 | |||
Orion Corporation's share capital comprises 141,257,828 shares, of which 45,194,218 are A shares and 96,063,610 are B shares. Each A share entitles its holder to twenty (20) votes and each B share to one (1) vote. Thus, the total number of votes is 999,947,970.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Contact person:
Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.